DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Information source: LEO Pharma
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psoriasis Vulgaris

Intervention: Calcipotriol, (calcipotriol + betamethasone) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: LEO Pharma

Official(s) and/or principal investigator(s):
S White, MD, Principal Investigator, Affiliation: Clatterbridge Hospital, Department of Dermatology

Summary

Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with:

1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream

2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate) ointment on weekends

3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of vehicle of calcipotriol cream

The objective is to compare the efficacy and safety of the different treatment regimens

Clinical Details

Official title: Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Efficacy of regimen (a) versus regimen (c) by % change in PASI at week 12

Secondary outcome: Efficacy of regimen (b) versus regimen (c) at week 12, safety of regimen (a) versus (c), safety of regimen (b) versus (c)

Detailed description: A phase IV study of different treatment regimens of calcipotriol 50 mcg/g cream and combination (calcipotriol 50 mcg/g plus betamethasone 0. 5 mg/g (as dipropionate)) ointment following treatment with combination ointment in psoriasis vulgaris

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with psoriasis vulgaris of trunk and/or limbs

Exclusion Criteria:

-

Locations and Contacts

Universitair Ziekenhuis, Gent 9000, Belgium

Hôpital Nord, Service de Dermatologie, Saint Etienne 42055, France

Klinikum der Goethe-Universität, Zentrum für Dermatologie und Venerologie, Frankfurt 60590, Germany

Canisius-Wilhelmina Ziekenhuis, Nijmegen 6532, Netherlands

Hospital Mutua de Terrassa Dermatology Service, Terrassa 08221, Spain

Clatterbridge Hospital, Department of Dermatology, Merseyside L63 4JY, United Kingdom

Dermatrials Research Dermatology Centre, Hamilton, Ontario L8N 1V6, Canada

Additional Information

Starting date: April 2005
Ending date: December 2005
Last updated: February 20, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008